These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Mast cell mediators cause early allergic bronchoconstriction in guinea-pigs in vivo: a model of relevance to asthma. Riley JP; Fuchs B; Sjöberg L; Nilsson GP; Karlsson L; Dahlén SE; Rao NL; Adner M Clin Sci (Lond); 2013 Dec; 125(11):533-42. PubMed ID: 23799245 [TBL] [Abstract][Full Text] [Related]
44. Role of MUC5AC in the pathogenesis of exercise-induced bronchoconstriction. Hallstrand TS; Debley JS; Farin FM; Henderson WR J Allergy Clin Immunol; 2007 May; 119(5):1092-8. PubMed ID: 17321575 [TBL] [Abstract][Full Text] [Related]
45. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Dahlén SE; Malmström K; Nizankowska E; Dahlén B; Kuna P; Kowalski M; Lumry WR; Picado C; Stevenson DD; Bousquet J; Pauwels R; Holgate ST; Shahane A; Zhang J; Reiss TF; Szczeklik A Am J Respir Crit Care Med; 2002 Jan; 165(1):9-14. PubMed ID: 11779723 [TBL] [Abstract][Full Text] [Related]
46. Effect of cysteinyl leukotriene receptor antagonist on CD11b and CD23 expression in asthmatic children. Gagro A; Aberle N; Rabatić S; Ajduk J; Jelacić J; Dekaris D Clin Exp Allergy; 2004 Jun; 34(6):939-44. PubMed ID: 15196283 [TBL] [Abstract][Full Text] [Related]
47. Cough, asthma, and cysteinyl-leukotrienes. Niimi A Pulm Pharmacol Ther; 2013 Oct; 26(5):514-9. PubMed ID: 23774534 [TBL] [Abstract][Full Text] [Related]
48. Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Peroni DG; Pescollderungg L; Sandri M; Chinellato I; Boner AL; Piacentini GL Respir Med; 2011 Dec; 105(12):1790-7. PubMed ID: 21865022 [TBL] [Abstract][Full Text] [Related]
49. Differential effects of fluticasone and montelukast on allergen-induced asthma. Palmqvist M; Bruce C; Sjöstrand M; Arvidsson P; Lötvall J Allergy; 2005 Jan; 60(1):65-70. PubMed ID: 15575933 [TBL] [Abstract][Full Text] [Related]
50. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Moinuddin R; deTineo M; Maleckar B; Naclerio RM; Baroody FM Ann Allergy Asthma Immunol; 2004 Jan; 92(1):73-9. PubMed ID: 14756468 [TBL] [Abstract][Full Text] [Related]
51. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Bronsky EA; Kemp JP; Zhang J; Guerreiro D; Reiss TF Clin Pharmacol Ther; 1997 Nov; 62(5):556-61. PubMed ID: 9390112 [TBL] [Abstract][Full Text] [Related]
52. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. Lee DK; Haggart K; Currie GP; Anderson SD; Lipworth BJ Br J Clin Pharmacol; 2003 Jun; 55(6):639-42. PubMed ID: 12814463 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Nayak AS; Philip G; Lu S; Malice MP; Reiss TF; Ann Allergy Asthma Immunol; 2002 Jun; 88(6):592-600. PubMed ID: 12086367 [TBL] [Abstract][Full Text] [Related]
54. Role of leukotrienes in exercise-induced bronchoconstriction. Hallstrand TS; Henderson WR Curr Allergy Asthma Rep; 2009 Jan; 9(1):18-25. PubMed ID: 19063820 [TBL] [Abstract][Full Text] [Related]
55. Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Steinshamn S; Sandsund M; Sue-Chu M; Bjermer L Scand J Med Sci Sports; 2002 Aug; 12(4):211-7. PubMed ID: 12199869 [TBL] [Abstract][Full Text] [Related]
56. Role of leukotrienes in exercise-induced bronchoconstriction before and after a pilot rehabilitation training program. El-Akkary IM; Abdel-Fatah Zel-K; El-Seweify Mel-S; El-Batouti GA; Aziz EA; Adam AI Int J Gen Med; 2013; 6():631-6. PubMed ID: 23930076 [TBL] [Abstract][Full Text] [Related]
57. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Kraft M; Cairns CB; Ellison MC; Pak J; Irvin C; Wenzel S Chest; 2006 Dec; 130(6):1726-32. PubMed ID: 17166989 [TBL] [Abstract][Full Text] [Related]
58. Exercise-induced alterations in phospholipid hydrolysis, airway surfactant, and eicosanoids and their role in airway hyperresponsiveness in asthma. Murphy RC; Lai Y; Nolin JD; Aguillon Prada RA; Chakrabarti A; Novotny MV; Seeds MC; Altemeier WA; Gelb MH; Hite RD; Hallstrand TS Am J Physiol Lung Cell Mol Physiol; 2021 May; 320(5):L705-L714. PubMed ID: 33533300 [TBL] [Abstract][Full Text] [Related]
59. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pajaron-Fernandez M; Garcia-Rubia S; Sanchez-Solis M; Garcia-Marcos L Pediatr Pulmonol; 2006 Mar; 41(3):222-7. PubMed ID: 16429427 [TBL] [Abstract][Full Text] [Related]
60. Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. Jayaram L; Duong M; Pizzichini MM; Pizzichini E; Kamada D; Efthimiadis A; Hargreave FE Eur Respir J; 2005 Jan; 25(1):41-6. PubMed ID: 15640321 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]